Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

Xiaofeng Li, Yazhou Zhang, Heeseog Kang, Wenzhong Liu, Peng Liu, Jianghong Zhang, Stephen E Harris, Dianqing Wu

Research output: Contribution to journalArticle

799 Citations (Scopus)

Abstract

The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass. In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293T cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by overexpression of Wnt co-receptor low density lipoprotein receptor-related protein (LRP) 5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transduction of canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the high bone mass phenotype associated with the loss of sclerostin may be attributed, at least in part, to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.

Original languageEnglish (US)
Pages (from-to)19883-19887
Number of pages5
JournalJournal of Biological Chemistry
Volume280
Issue number20
DOIs
StatePublished - May 20 2005

Fingerprint

Osteoblasts
Low Density Lipoprotein Receptor-Related Protein-5
Wnt Receptors
Bone and Bones
Osteocalcin
Bone
Epidermal Growth Factor
Osteogenesis
Kidney
Genes
MASS syndrome
Sclerosteosis

ASJC Scopus subject areas

  • Biochemistry

Cite this

Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., ... Wu, D. (2005). Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. Journal of Biological Chemistry, 280(20), 19883-19887. https://doi.org/10.1074/jbc.M413274200

Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. / Li, Xiaofeng; Zhang, Yazhou; Kang, Heeseog; Liu, Wenzhong; Liu, Peng; Zhang, Jianghong; Harris, Stephen E; Wu, Dianqing.

In: Journal of Biological Chemistry, Vol. 280, No. 20, 20.05.2005, p. 19883-19887.

Research output: Contribution to journalArticle

Li, X, Zhang, Y, Kang, H, Liu, W, Liu, P, Zhang, J, Harris, SE & Wu, D 2005, 'Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling', Journal of Biological Chemistry, vol. 280, no. 20, pp. 19883-19887. https://doi.org/10.1074/jbc.M413274200
Li, Xiaofeng ; Zhang, Yazhou ; Kang, Heeseog ; Liu, Wenzhong ; Liu, Peng ; Zhang, Jianghong ; Harris, Stephen E ; Wu, Dianqing. / Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. In: Journal of Biological Chemistry. 2005 ; Vol. 280, No. 20. pp. 19883-19887.
@article{3f5b5ce7883346c3be83e8a61497a019,
title = "Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling",
abstract = "The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass. In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293T cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by overexpression of Wnt co-receptor low density lipoprotein receptor-related protein (LRP) 5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transduction of canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the high bone mass phenotype associated with the loss of sclerostin may be attributed, at least in part, to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.",
author = "Xiaofeng Li and Yazhou Zhang and Heeseog Kang and Wenzhong Liu and Peng Liu and Jianghong Zhang and Harris, {Stephen E} and Dianqing Wu",
year = "2005",
month = "5",
day = "20",
doi = "10.1074/jbc.M413274200",
language = "English (US)",
volume = "280",
pages = "19883--19887",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "20",

}

TY - JOUR

T1 - Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling

AU - Li, Xiaofeng

AU - Zhang, Yazhou

AU - Kang, Heeseog

AU - Liu, Wenzhong

AU - Liu, Peng

AU - Zhang, Jianghong

AU - Harris, Stephen E

AU - Wu, Dianqing

PY - 2005/5/20

Y1 - 2005/5/20

N2 - The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass. In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293T cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by overexpression of Wnt co-receptor low density lipoprotein receptor-related protein (LRP) 5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transduction of canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the high bone mass phenotype associated with the loss of sclerostin may be attributed, at least in part, to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.

AB - The loss of the SOST gene product sclerostin leads to sclerosteosis characterized by high bone mass. In this report, we found that sclerostin could antagonize canonical Wnt signaling in human embryonic kidney A293T cells and mouse osteoblastic MC3T3 cells. This sclerostin-mediated antagonism could be reversed by overexpression of Wnt co-receptor low density lipoprotein receptor-related protein (LRP) 5. In addition, we found that sclerostin bound to LRP5 as well as LRP6 and identified the first two YWTD-EGF repeat domains of LRP5 as being responsible for the binding. Although these two repeat domains are required for transduction of canonical Wnt signals, canonical Wnt did not appear to compete with sclerostin for binding to LRP5. Examination of the expression of sclerostin and Wnt7b, an autocrine canonical Wnt, during primary calvarial osteoblast differentiation revealed that sclerostin is expressed at late stages of osteoblast differentiation coinciding with the expression of osteogenic marker osteocalcin and trailing after the expression of Wnt7b. Given the plethora of evidence indicating that canonical Wnt signaling stimulates osteogenesis, we believe that the high bone mass phenotype associated with the loss of sclerostin may be attributed, at least in part, to an increase in canonical Wnt signaling resulting from the reduction in sclerostin-mediated Wnt antagonism.

UR - http://www.scopus.com/inward/record.url?scp=21244480924&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244480924&partnerID=8YFLogxK

U2 - 10.1074/jbc.M413274200

DO - 10.1074/jbc.M413274200

M3 - Article

C2 - 15778503

AN - SCOPUS:21244480924

VL - 280

SP - 19883

EP - 19887

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 20

ER -